Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that were sustained through week 36. The Regeneron data were published by The New England Journal of Medicine and simultaneously presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) treated continuously with AMVUTTRA had lower rates of the composite of all-cause mortality and recurrent cardiovascular events, better-preserved quality of life and greater stability of cardiac biomarkers through five years than patients who initiated treatment with AMVUTTRA approximately three years later. A separate post hoc analysis of HELIOS-B provides new physiologic insight into the effects of AMVUTTRA during exercise, demonstrating preserved exercise capacity and favorable effects across multiple components of the cardiopulmonary response to exercise compared with placebo.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London.

Wall Street's median target prices suggest these are the three best Nasdaq-100 stocks to buy right now.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi-powered transthyretin (TTR) silencing with AMVUTTRA® (vutrisiran), including long-term cardiovascular outcomes and functional measures, while providing new insights into the multisystemic manifestations of transthyretin-mediated amyloidosis (ATTR) and opportunities for earlier diagnosis and treatment.

AMVUTTRA revenue jumped 65% year over year as TTR franchise momentum accelerates.

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as growth in its transthyretin, or TTR, franchise continued to drive results. Chief Executive Officer Yvonne Greenstreet said

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2026, and reviewed recent business highlights.

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington’s disease, reporting dose-dependent reductions in cerebrospinal fluid mutant huntingtin after a single intrathecal dose and plans to begin a placebo-controlle

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington’s Disease Network (EHDN) Clinical Research Congress 2026 in Krakow, Poland.

This beaten-down biotech has a better story than its stock chart suggests.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open.

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play’ aims to help people recognize the symptoms of ATTR-CM earlier and encourage informed conversations with healthcare professionals to help patients advocate for their diagnosis and treatment.

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk. Duri

Analysts think Alnylam could rebound strongly over the next 12 months.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 15.67%. Currently, Alnylam Pharmaceuticals has a market